Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152575 · ClinicalTrials.gov registry record · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A Phase 3 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT06152575 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 492 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06152575, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Elranatamab
- DRUG Pomalidomide
- DRUG Bortezomib
- DRUG Elotuzumab
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- Community Cancer Institute - Clovis
- Clinical Research Advisors (Encino Satellite Location) - Encino
- Hoag Health Center Irvine - Irvine
- Hoag Hospital Irvine - Irvine
- Clinical Research Advisors (Korea Town Satellite Location) - Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location) - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Mission Community Hospital (Satellite Site) - Panorama City
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- University of California - Sacramento
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- UCHealth Longs Peak Hospital - Longmont
- UCHealth Longs Peak Medical Center - Longmont
- UCHealth - Medical Center of the Rockies - Loveland
Alabama
- Infirmary Cancer Care - Mobile
Arizona
- Western Regional Medical Center, Inc. dba. City of Hope Phoenix - Goodyear
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2024-02-08 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06152575
The ClinicalTrials.gov registry entry for NCT06152575 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (10% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT06152575 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06152575 about?
NCT06152575 is a clinical study titled "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)". The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments bef...
What is the current status of trial NCT06152575?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2024-02-08. Estimated completion is 2027-12-30.
What conditions does trial NCT06152575 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06152575?
The interventions under investigation include: Dexamethasone (DRUG), Elranatamab (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), Elotuzumab (DRUG).
Who is sponsoring clinical trial NCT06152575?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06152575 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.